1. Home
  2. TRUP vs DSGN Comparison

TRUP vs DSGN Comparison

Compare TRUP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trupanion Inc.

TRUP

Trupanion Inc.

HOLD

Current Price

$26.92

Market Cap

948.7M

Sector

Health Care

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$15.01

Market Cap

860.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRUP
DSGN
Founded
2000
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
948.7M
860.7M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
TRUP
DSGN
Price
$26.92
$15.01
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$45.80
$15.25
AVG Volume (30 Days)
375.7K
965.7K
Earning Date
04-30-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
295.65
N/A
EPS
0.11
N/A
Revenue
$1,439,305,000.00
N/A
Revenue This Year
$11.79
N/A
Revenue Next Year
$8.83
N/A
P/E Ratio
$245.91
N/A
Revenue Growth
11.95
N/A
52 Week Low
$21.16
$3.76
52 Week High
$57.00
$17.25

Technical Indicators

Market Signals
Indicator
TRUP
DSGN
Relative Strength Index (RSI) 70.74 66.10
Support Level $24.47 $9.78
Resistance Level $27.07 $17.10
Average True Range (ATR) 1.02 1.08
MACD 0.36 0.24
Stochastic Oscillator 87.32 83.56

Price Performance

Historical Comparison
TRUP
DSGN

About TRUP Trupanion Inc.

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: